Immunovia Publ Current Valuation vs. Cash And Equivalents
| IMMNOV Stock | SEK 0.85 0.20 30.77% |
For Immunovia Publ profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunovia Publ to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunovia publ AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunovia Publ's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunovia publ AB over time as well as its relative position and ranking within its peers.
Immunovia |
Immunovia publ AB Cash And Equivalents vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunovia Publ's current stock value. Our valuation model uses many indicators to compare Immunovia Publ value to that of its competitors to determine the firm's financial worth. Immunovia publ AB is considered the number one company in current valuation category among its peers. It also is currently regarded as number one stock in cash and equivalents category among its peers creating about 0.67 of Cash And Equivalents per Current Valuation. The ratio of Current Valuation to Cash And Equivalents for Immunovia publ AB is roughly 1.49 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunovia Publ by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunovia Publ's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Immunovia Current Valuation vs. Competition
Immunovia publ AB is considered the number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Diagnostics & Research industry is currently estimated at about 7.25 Billion. Immunovia Publ holds roughly 536.89 Million in current valuation claiming about 7% of equities under Diagnostics & Research industry.
Immunovia Cash And Equivalents vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Immunovia Publ |
| = | 536.89 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Immunovia Publ |
| = | 359.85 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Immunovia Cash And Equivalents Comparison
Immunovia Publ is currently under evaluation in cash and equivalents category among its peers.
Immunovia Publ Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunovia Publ, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunovia Publ will eventually generate negative long term returns. The profitability progress is the general direction of Immunovia Publ's change in net profit over the period of time. It can combine multiple indicators of Immunovia Publ, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.
Immunovia Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunovia Publ. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunovia Publ position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunovia Publ's important profitability drivers and their relationship over time.
Use Immunovia Publ in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunovia Publ position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovia Publ will appreciate offsetting losses from the drop in the long position's value.Immunovia Publ Pair Trading
Immunovia publ AB Pair Trading Analysis
The ability to find closely correlated positions to Immunovia Publ could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunovia Publ when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunovia Publ - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunovia publ AB to buy it.
The correlation of Immunovia Publ is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunovia Publ moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunovia publ AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunovia Publ can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immunovia Publ position
In addition to having Immunovia Publ in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Theme ETFs Thematic Idea Now
Theme ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Immunovia Stock
To fully project Immunovia Publ's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunovia publ AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunovia Publ's income statement, its balance sheet, and the statement of cash flows.